CClinicalTrials.gg
CompletedNCT05258812Updated Feb 28, 2022

Cytopenias in Hospitalized Patients of Corona Virus Infection(COVID-19) During First and Other Waves

An observational study in Corona Virus Infection, sponsored by Fatima Memorial Hospital. Completed at 1 site in Pakistan. Open to participants aged 10 Years to 95 Years. Per ClinicalTrials.gov, last updated 2022-02-28.

Sponsored by Fatima Memorial Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
202
Ages
10 Years to 95 Years
Sex
All
01

Study summary

Demographic, Clinical and laboratory data as well as outcome of total 202 COVID-19 patients who were Polymerase Chain Reaction (PCR) positive and admitted in Fatima memorial Hospital, Lahore, Pakistan, was collected during first and other waves. Data of First wave is from May 2020 to July 2020, second wave from early November to Mid December 2020 and third wave from Mid march to June 2021. Investigator analyzed the data on basis of Systemic immune inflammatory index (SII) as well hematological parameters of First Wave were compared to other waves of COVID-19.

02

Conditions studied

  • Corona Virus Infection

Keywords

  • COVID-19
  • Cytopenia
  • Thrombocytopenia
  • Anemia
  • Leucopenia
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 202 is below the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Fatima Memorial Hospital is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

COVID-19 Positive Hospitalized patients, of all genders and all age group.

Inclusion criteria

  • COVID-19 Positive Hospitalized patients
  • All genders

Exclusion criteria

Exclusion Criteria:

  • Patients with Known hematological disorders
  • Patients with known chronic Liver Disease
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
202 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Cytopenias in Hospitalized Patients of COVID-19 During First and Other waves

    extent of cytopenias is being measured in COVID-19 hospitalized patients.

    Time frame: 4 weeks

07

Study locations

1 site
  • Fatima memorial Hospital
    Lahore, Punjab 54000, Pakistan
08

References and documents

Study documents

  • Study protocol · Jan 15, 2022

Documents are hosted by the registry — open the source record to download them.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05258812
Lead sponsor
Fatima Memorial Hospital
Responsible party
Ambreen Kashif (Doctor, Fatima Memorial Hospital) — Principal investigator
First posted
Feb 28, 2022
Start date
May 1, 2020
Primary completion
Jun 30, 2021
Completion
Jun 30, 2021
Last update
Feb 28, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion